---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Executive summary: Disease burden"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Disease burden. Topics: Summary: epidemiology, Summary: survival and mortality, and Summary: humanistic and economic burden. 3 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary/disease-burden"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Executive summary: Disease burden

<a id="heading-1.1.1"></a>

## 1.1.1 Burden of HPV-negative head and neck squamous cell carcinoma

<a id="topic-1.1.1-1"></a>

### Summary: epidemiology

The American Cancer Society estimates 60,480 new cases of oral cavity and pharynx cancer in the United States in 2026, and Siegel et al. estimate a further 12,290 new cases of laryngeal cancer. SEER reports 461,008 people living with oral cavity and pharynx cancer and 87,355 living with laryngeal cancer in 2023. These counts cover all cancers of these sites, of any histology and HPV status; no source in the evidence states the U.S. incidence or prevalence of HPV-negative HNSCC or of recurrent or metastatic disease. Most tumors of the oral cavity, larynx, and hypopharynx are HPV-negative. Among U.S. oropharyngeal cancers in 2012 to 2016, an average of 5,500 of 19,000 annual cases (29%) were HPV-negative.

The HPV-negative share of recurrent or metastatic HNSCC differs by source. Bicara states that “Approximately 80% of patients with R/M HNSCC are HPV-negative.” In KEYNOTE-048, 22% of tumors were HPV-positive. Among U.S. real-world first-line pembrolizumab recipients, 258 (39.9%) had HPV-negative tumors, 233 (36.1%) HPV-positive, and 155 (24.0%) equivocal or unknown. Across all HNSCC, the median age at diagnosis is 66 years for HPV-negative disease, 10% of patients have metastatic disease at diagnosis, and approximately 50% of those with locally advanced disease have recurrence or metastasis after initial therapy (Bicara states “up to 30%”). In SEER-Medicare data on older adults with locally advanced HNSCC, 333 of the resected cohort (66%) and 791 of the unresected cohort (65%) had recurrence.

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf); [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/); [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html); [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html); [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Senkomago et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6705893/); [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated); [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/); [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

<a id="topic-1.1.1-2"></a>

### Summary: survival and mortality

For all oral cavity and pharynx cancer, SEER reports five-year relative survival of 69.9% overall and 36.0% for the 12% of cases diagnosed at a distant stage; the American Cancer Society estimates 13,150 deaths in 2026. For all laryngeal cancer, five-year relative survival is 62.5% overall and 36.0% at a distant stage (15% of cases), with an estimated 3,960 deaths in 2026. In oropharyngeal cancer, HPV-negative disease had shorter survival than HPV-positive disease: median survival of 20 versus 131 months in a U.S. population-based series, and 3-year overall survival of 57.1% versus 82.4% in a second oropharyngeal cancer cohort (Ang et al., 2010). In first-line recurrent or metastatic HNSCC treated with pembrolizumab in U.S. practice, median real-world overall survival was 9 months with HPV-negative versus 20 months with HPV-positive tumors on monotherapy, and 7 versus 15 months on pembrolizumab plus chemotherapy. In the KEYNOTE-048 total population (all HNSCC), 5-year overall survival was 14.4% with pembrolizumab and 16.0% with pembrolizumab-chemotherapy, versus 6.5% and 5.2% with EXTREME. Among older SEER-Medicare adults with locally advanced HNSCC, median overall survival after recurrence was 23.8 months (resected) and 23.7 months (unresected), against 44.4 and 64.5 months without recurrence.

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html); [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html); [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf); [Chaturvedi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3221528/); [Ang et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2943767/); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/); [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

<a id="topic-1.1.1-3"></a>

### Summary: humanistic and economic burden

The burden figures available cover head and neck cancer or HNSCC as a whole; none is specific to HPV-negative disease. In a secondary analysis, 99 of 230 assessable participants (43%) had a severe late toxicity. Swallowing and speech impairments occur in about 50% of HNSCC survivors after radiotherapy, and HNSCC survivors have a suicide rate of 63.4 cases per 100,000 individuals. In a retrospective study using the Vector Oncology Data Warehouse, the mean monthly health care cost was $14,391, with hospitalization accounting for about 57%. In Medicare and commercial claims from 2004 to 2008, 6-month incremental adjusted total costs were $60,414 per patient for metastatic and $21,141 for recurrent head and neck cancer. In SEER-Medicare, recurrence was associated with higher monthly costs of $3,831 (resected) and $4,730 (unresected). Among participants with head and neck cancer in a study of several cancer types, 66.7% noted that recurrence affected employment, and 25.9% of patients and 44.4% of caregivers in a separate head and neck cancer study reported high financial toxicity.

Source: [Machtay et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4911537/); [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/); [Fisher et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29530457/); [Kim et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22475042/); [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/); [Aguiar-Ibáñez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11792841/); [Nguyen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10116977/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
